4 completed, 2 terminated. 3 Phase 1, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow avoralstat: new trials by email Literature Review of avoralstat trials Research Report on avoralstat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Avoralstat In Participants With Diabetic Macular Edema avoralstat - Diabetic Macular Edema (DME) | Phase 1 | Terminated | BioCryst Pharmaceuticals | 3 | 2025-10-02 | 2026-05-11 |
| Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema avoralstat - Hereditary Angioedema, HAE | Phase 3 | Terminated | BioCryst Pharmaceuticals | 6 | 2015-12-01 | 2016-02-17 |
| 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks BCX4161, Placebo - Hereditary Angioedema, HAE | Phase 2 / Phase 3 | Completed | BioCryst Pharmaceuticals | 110 | 2014-12-17 | 2025-11-17 |
| Study to Determine How BCX4161 is Metabolized and Eliminated by the Body BCX4161 - Hereditary Angioedema | Phase 1 | Completed | BioCryst Pharmaceuticals | 7 | 2014-08-01 | 2014-10-29 |
| A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161 BCX4161 - Hereditary Angioedema | Phase 1 | Completed | BioCryst Pharmaceuticals | 28 | 2014-04-01 | 2014-08-15 |
| Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE BCX4161, Placebo - Hereditary Angioedema | Phase 2 | Completed | BioCryst Pharmaceuticals | 24 | 2013-11-01 | 2014-08-18 |
United Kingdom (4) · Belgium (2) · France (2) · Germany (2) · United States (2) · Australia (1) · Canada (1) · Hungary (1) · Italy (1)
Henriette Farkas, MD, PhD, DSc (1) · Joanne Collier (1) · Joanne Collier, MBChB, FFPM, Dip Stats (OU) (1) · Marc Riedl, MD MS (1) · Marcus Maurer, MD (1)